Latest news with #Teston
Mint
06-07-2025
- Sport
- Mint
Akash Deep's six-fer powers India to break 58-year-old Birmingham jinx as Shubman Gill records first win as Test captain
Five-wicket hauls from Akash Deep and Mohammed Siraj and a double hundred and a century from captain Shubman Gill set up India's historic win at Edgbaston in Birmingham against England in the second Teston Sunday. Having played at this ground from 1967, this was India's first-ever win at this ground in ninth attempt. India level series 1-1. Chasing a mammoth 608 runs for victory, England started on 72/3 on the fifth and final day, the start of which was delayed due to rain. But the delay couldn't deter the Indian bowlers, especially Akash Deep, who finished with 6/99 - his maiden five-wicket haul in international cricket. In the process, Akash Deep, who was brought in place of Jasprit Bumrah for this Test, finished the game with a 10-wicket haul and kept India alive in the Anderson-Tendulkar trophy. Year Opponent Margin Result 1967 England By 132 runs Lost 1974 England By an innings & 78 runs Lost 1979 England By an innings & 83 runs Lost 1986 England - Drawn 1996 England By 8 wickets Lost 2011 England By an innings & 242 runs Lost 2018 England By 31 runs Lost 2022 England By 7 wickets Lost 2025 England Win
GMA Network
01-07-2025
- Health
- GMA Network
FDA: Dengue, ASF vaccines still pending approval
The Food and Drug Administration (FDA) said Tuesday they are still processing the approval of vaccines intended to counter Dengue and African Swine Fever. During an ambush interview on Tuesday, FDA Director General Paolo Teston said they are still waiting for several required documents for post-approval from the applicants of the ASF vaccine. 'Nag-uundergo po siya ng post-approval commitment compliance po ng naaprubahan po na una ng FDA. Marami pa pong submission requirements po… Ang FDA naman po ay patuloy na naghihintay sa submissions, sa pagsusumite ng nabigyan po ng monitored release ng certificate of product registration (CPR),' he shared. (It is undergoing post-approval commitment compliance when it was initially approved by the FDA. There are still a lot of submission requirements… The FDA continues to wait for submissions for those granted with monitored release of the CPR.) Teston said that compliance with the needed submissions may be enough for a CPR, but that applicants would still need to comply with post-approval commitments. He added the ASF vaccine is undergoing scrutiny from the FDA's fact-finding committee. 'Sana po pwede ko sabihin na yesterday yung timeline namin [ng approval], pero ang FDA po talaga ang concern niya is health and safety ng mga produkto. We cannot compromise po yung safety ng produkto na gagamitin sa ating livestock, particularly sa mga baboy po, para lang po mapabilis yung proseso,' he said. (I hope I could say that our timeline [of approval] was yesterday, but the FDA's concern is the health and safety of these products. We cannot compromise the safety of the product that will be used on our livestock, particularly on pigs, just to speed up the process.) Teston said should applicants be able to properly submit all necessary documents, the vaccine should be approved within the year. 'Kailangan lang din po namin sagutin yung ibang issue kasama yung pre-approval na natanong po nung nagkaroon po ng inquiry sa Congress about dito sa ASF vaccine,' he said. (We just have to address the other issues, including the pre-approval that had been raised during a Congress inquiry about the ASF vaccine.) Meanwhile, Teston shared that TAC-003 or QDenga vaccine against dengue is now being assessed by an FDA expert panel. The QDenga vaccine is an live-attenuated vaccine with an 80% first year post-vaccination efficacy against Virologically Confirmed Dengue (VCD) fever, recommended for prevention of the disease in people who had never been infected and had already been approved in more than 40 countries with over 10 million doses distributed nationwide. 'Ito ay sumasailalim sa pagsusuri ng expert panel both po ng FDA at pati expert panel ng external ng FDA,' he said. (This is undergoing an investigation from the FDA's expert and external expert panels.) 'Independent po kasi yung expert panel ng FDA dahil sila po yung nakakaalam, sila po yung nag-aassure ng quality and safety and efficacy ng produkto, lalo na pag bago yung produkto,' Teston added. (The FDA expert panel is independent because they are the ones whom understand, and they are the ones that assure the quality and safety and efficacy of the product, especially if the product is new.) The FDA notes that approvals of the vaccine undergo a whole of government approach and acknowledged the urgent need of both vaccines to combat the spread of Dengue and ASF in the country. 'Ina-acknowledge po naman natin yung need for the vaccine and relatively po, fina-facilitate po siya ng FDA as long as there are no standards violated and the safety of the Filipinos who will be inoculated with the vaccine will be assured… Sana pwede ko din sabihin na yesterday yung lead time [sa release ng bakuna], pero sa lalong madaling panahon po sana [ma-approve na],' Teston said. (We are acknowledging the need for the vaccine and relatively, the FDA is facilitating it as long as there are no standards violated and the safety of the Filipinos who will be inoculated with the vaccine will be assured… I hope I can also say that the lead time [fpr the release of the vaccine] was yesterday, but I hope it [gets approved] as soon as possible.) —RF, GMA Integrated News
